Answer
Catridecacog (NovoThirteen) replaces the factor XIII A-subunit, which, after activation, cross-links fibrin and other proteins, strengthening clots, increasing resistance to breakdown and improving platelet and clot adhesion to injured tissue.
Sources for this answer
- NovoThirteen 2500 IU powder and solvent for solution for injectionNovo Nordisk Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked